Proteome Sciences PLC Launch of new services powered by TMTpro 16plex (9032D)
01 Julio 2019 - 01:00AM
UK Regulatory
TIDMPRM
RNS Number : 9032D
Proteome Sciences PLC
01 July 2019
1 July 2019
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Launch of new services powered by TMTpro 16plex
Following the announcement of TMTpro 16plex isobaric mass tags
during the American Society for Mass Spectrometry (ASMS) meeting in
Atlanta in June, Proteome Sciences is launching upgrades to its
core proteomic services (SysQuant(R) , TMTcalibrator(TM) and Plasma
Super Depletion) with increased multiplexing. Testing has shown
that these new reagents perform equivalently to the current 11-plex
TMT(R) in terms of the numbers of quantified peptides and proteins,
whilst providing a 50% increase in the number of samples that can
be analysed in a single experiment.
TMTpro is a completely re-designed set of isobaric mass tags
developed and patented by Proteome Sciences, with multiple benefits
over the previous TMT reagents. As well as offering five extra
channels, the new chemistry also provides a 9-plex set of
single-Dalton resolved tags for use with TMT complement ion
quantification. In addition, the reporter ion is more readily
fragmented and offers gains in signal-to-noise both in MS2 and MS3
analyses.
Adding TMTpro 16-plex reagents to standard service workflows
will provide significant benefits to clients in both the size and
speed of biomarker discovery projects.
Commenting on the announcement Dr Ian Pike, Chief Scientific
Officer, said "We are delighted to be introducing TMTpro into our
proprietary biomarker services. Proteome Sciences is the only
contract research organisation able to provide clients access to
the higher plexing rates and extended performance of TMTpro. This
is a critical element enabling the power of proteomics to support
larger cohort studies which will be increasingly necessary to
deliver precision medicines."
For further information:
Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043 2116
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEVLFLKQFLBBE
(END) Dow Jones Newswires
July 01, 2019 02:00 ET (06:00 GMT)
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024